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Diabetes and periodontitis
Robert Hirsch, Senior Lecturer, Dental School, The University of Adelaide, Adelaide 
Summary
Chronic gingivitis and periodontitis are common 
inflammatory conditions of the periodontal 
tissues. Given the ‘right’ concurrence of risk 
factors, a person with periodontitis can experience 
significant destruction of tooth-supporting 
bone, ultimately resulting in tooth loss. Poorly 
controlled diabetes is an important risk factor 
for periodontitis, and gingivitis and periodontitis 
are sometimes the first sign that a patient has 
diabetes. As severe periodontitis can lead to the 
loss of teeth, it is important that patients with 
diabetes practise good oral hygiene and have 
regular dental check-ups so that problems can be 
detected quickly. 
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Introduction
In chronic periodontitis, the tooth supporting structures (alveolar 
bone and the periodontal ligament) are destroyed. The disease 
has a multifactorial origin. Complexes of commensal oral 
anaerobic bacteria and perhaps viruses are thought to interact 
with risk factors, such as smoking, diabetes and depression, 
to create the conditions which make a person susceptible to 
periodontitis. The patient’s immuno-inflammatory response 
to the bacteria causes the tissue destruction which occurs in 
chronic periodontitis. Less than 5% of Australians are susceptible 
to the severe periodontitis which results in tooth loss, although 
up to 10% experience moderate amounts of periodontitis-related 
bone loss. 
It is useful to distinguish chronic gingivitis from periodontitis. 
Chronic gingivitis is the very common inflammatory reaction 
occurring in the gingival tissues in response to the accumulation 
of dental plaque. It usually precedes the development of 
periodontitis, but chronic gingivitis does not inevitably progress 
to periodontitis. The clinical appearance of gingivitis may be 
modified by systemic factors such as poorly controlled diabetes, 
which can significantly accentuate the gingival tissues’ response 
to dental plaque (Fig. 1).
The relationship between diabetes, gingivitis 
and periodontitis 
Although periodontitis is a recognised complication of diabetes, 
people with well-controlled diabetes who have good oral 
hygiene are not at increased risk of periodontitis. However, 
their susceptibility to periodontitis is significantly increased 
when their diabetes is poorly controlled, particularly if they also 
smoke. 
Recent epidemiologic evidence shows that the prevalence of 
diabetes in patients with periodontitis is significantly greater 
(by two times) than in people without periodontitis.1 Given 
that diabetes may be present for a number of years before it 
is diagnosed, and that the prevalence of diabetes is increasing 
in the Australian community, dentists may be the first health 
professionals to detect a patient’s diabetes. The gingival and 
periodontal signs which may alert the clinician that the patient 
has previously undiagnosed diabetes or that the patient’s 
diabetes is poorly controlled, include: 
  persistence of gingival inflammation after standard 
periodontal treatment (thorough supra- and subgingival 
scaling and cleaning, oral hygiene instruction)
  severe gingival inflammatory response to plaque and 
proliferation of gingival tissues at the gingival margin (Fig. 1)
Fig. 1
Severe gingival inflammatory reaction to dental plaque 
This 55-year-old patient has recently diagnosed type 2 
diabetes. The gingival tissue is friable, oedematous and 
prone to bleeding on tooth brushing.
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  continuing alveolar bone loss despite periodontal treatment 
(Fig. 2)
  severe, aggressive periodontitis in people 20–45 years of age 
(deep periodontal pocketing, increased tooth mobility and 
tooth migration, causing teeth to over-erupt or spaces to 
open between teeth, and radiographic evidence of advanced 
bone loss)
  simultaneous formation of multiple periodontal abscesses 
(Fig. 3).2 
How diabetes increases susceptibility to 
periodontitis 
Advanced glycation end products deposited in the tissues 
as a result of hyperglycaemia can alter the phenotype of 
macrophages and other cells via a specific cell-surface receptor. 
Macrophages are key cells in the pathogenesis of periodontitis 
through their ability to produce a large array of cytokines. They 
also influence the inflammatory response, the metabolism of 
fibroblasts and lymphocytes and stimulate bone resorption 
via prostaglandin E2. It is thought that the advanced glycation 
end products transform the macrophages into cells with a 
destructive phenotype, producing pro-inflammatory cytokines in 
an uncontrolled fashion.3 
Neutrophils are the primary defence cells of the periodontium. 
The reduced neutrophil function observed in patients with 
diabetes is therefore another mechanism increasing the 
susceptibility to periodontitis. 
Is there a relationship between periodontitis 
and the ability to control diabetes?
While periodontitis is a recognised complication of poorly 
controlled diabetes, it has been proposed that severe 
periodontitis may make the metabolic control of diabetes more 
difficult. The process may be mediated through the systemic 
release of inflammatory cytokines (e.g. TNF-α) from periodontitis 
lesions, and chronic, low-level systemic exposure to Gram 
negative organisms. Although early studies have been poorly 
designed, one of these suggested that when antibiotics were 
added to standard periodontal treatment (debridement of the 
teeth and oral hygiene improvement), diabetic control improved 
significantly for a period of three months.2
What can the patient do?
People with diabetes need to practise high standards of daily 
oral hygiene, including brushing and flossing. The use of 
interdental brushes (which are like small bottle brushes) is 
indicated where there has been some recession of the gingivae. 
Adjunctive use of a chlorhexidine mouthwash (0.12%) or 
chlorhexidine gel (0.2%) twice daily (used independently of 
toothpaste so that the chlorhexidine is not inactivated) may be 
useful in controlling the more severe forms of gingivitis. Patients 
should consult with their dentist or periodontist regarding the 
recommended duration of use of chlorhexidine. Dental care, 
which is specifically aimed at monitoring the health of the 
periodontal tissues and providing the necessary treatment, is 
needed at six-month intervals. 
Medical practitioners who suspect a patient has diabetes-related 
gingivitis or periodontitis should ensure that an early referral 
is made to a dentist. Dentists in turn need to refer advanced or 
suspect cases to a periodontist.
Fig. 2
Alveolar bone loss
This orthopantomograph of a 54-year-old patient with poorly 
controlled diabetes shows extensive alveolar bone loss 
involving most teeth. The destruction of bone has been rapid 
even though the patient has been undergoing periodontal 
therapy.
Fig. 3
Periodontal abscess formation 
This 56-year-old patient has poorly controlled type 2 
diabetes. The lower left lateral incisor (*) is very mobile and 
has migrated from its usual location in the arch. The tooth 
has lost more than two-thirds of its supporting bone because 
of periodontitis.
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Conclusion
Medical and dental practitioners need to be aware of the 
interrelationship between poorly controlled or undiagnosed 
diabetes mellitus and chronic gingivitis and periodontitis. This 
is particularly important because of the rising prevalence of 
diabetes in the Australian community.
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Self-test questions
The following statements are either true or false 
(answers on page 51)
3. Periodontitis may be the first presentation of diabetes.
4. Gingivitis precedes periodontitis.
3. Mealy B. Position paper. Diabetes and periodontal diseases. 
J Periodontol 2000;71:664-78. 
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Introducing the Adverse Medicine Events Line 
1300 134 237
Traditionally, only health professionals have reported adverse 
drug reactions to the Adverse Drug Reactions Advisory 
Committee (ADRAC). However, recent studies have shown that 
when consumers report adverse drug reactions, the reports are 
received more quickly, about a broader range of reactions and 
give a better account of the event. In addition, adverse reactions 
from complementary medicines are more likely to be reported 
by consumers.
Consumer reporting of adverse drug reactions has become a 
reality in Australia with the launch of a new telephone hotline 
called the Adverse Medicine Events (AME) Line. Operated by 
clinical pharmacists from Mater Health Services in Brisbane, 
the AME Line is a telephone service through which consumers 
can seek information about or report adverse events associated 
with medicines, including adverse drug reactions, errors and 
so-called ‘near misses’. 
The service, which is an initiative of the Australian Council for 
Safety and Quality in Health Care was launched in October 2003. 
It will operate from 9am to 6pm, Monday to Friday for an initial 
period of 18 months. Objectives of the AME Line are to:
  create a system for consumers to report adverse experiences 
with medicines
  promote openness and accuracy regarding adverse medicine 
events 
  identify trends in adverse medicine events to know when, 
where and how things go wrong 
  ultimately integrate the information into health systems, to 
improve safety and quality.
The pharmacists operating the AME Line can provide 
information or answer questions regarding medication-related 
adverse effects and ensure that adverse drug reaction reports 
satisfying specific criteria are submitted to ADRAC. Individuals 
are not named in these reports, but rather safety and quality 
issues within the system are identified. Medication errors and 
'near misses' are reported to the Australian Council for Safety 
and Quality in Health Care. De-identified data will be collected 
and fed back to health professionals to assist in changing 
systems to help prevent the recurrence of these adverse events.
Health professionals are encouraged to refer consumers to the 
AME Line, for information, advice and reporting of adverse 
medicine events. Further information about the line is available 
at: www.safetyandquality.org.au or by contacting Geraldine 
Moses or Treasure McGuire on (07) 3840 8087.
